, Tracking Stock Market Picks
Enter Symbol:
Cellectar Biosciences Inc. (CLRB) [hlAlert]

Mkt Outperform
up 162.71 %

Novelos Therapeutics (NVLT) rated Mkt Outperform with price target $3 by Rodman & Renshaw

Posted on: Friday,  Apr 11, 2008  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Cellectar Biosciences Inc. (NASDAQ: CLRB) on 04/11/2008, when the stock price was $1.18.
Since then, Cellectar Biosciences Inc. has gained 162.71% as of 08/25/2015's recent price of $3.10.
If you would have followed this Rodman & Renshaw's recommendation on CLRB, you would have gained 162.71% of your investment in 2692 days.

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the Company?s lead compound, is in Phase III development for treatment of lung cancer under a special protocol assessment and fast track. NOV-002 is also in Phase II development for treatment of early-stage breast cancer and chemotherapy-resistant ovarian cancer. NOV-205, Novelos? second compound, is in Phase Ib development for chronic hepatitis C non responders. Both compounds have completed clinical trials in humans and have been approved for use in Russia where they were originally developed.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/11/2008 8:25 AM Buy
1.18 6.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy